FDA Peptide Regulations 2026: Category 1 Classifications, the Compounding Ban & Research Availability

The regulatory landscape surrounding peptides underwent significant changes in 2025 and into 2026, reshaping how researchers, laboratories, and procurement teams approach peptide acquisition and study design. Understanding the FDA’s current classification framework — particularly the distinction between Category 1 peptides subject to compounding restrictions and those that remain accessible for legitimate laboratory research — is now a foundational requirement for any serious peptide research program. This guide synthesizes the current regulatory environment and clarifies which compounds remain available through research-use channels.

Researchers who have followed the trajectory of FDA peptide oversight will recognize that the 2024–2026 period marked a pivotal shift in how certain synthetic peptides are categorized under 503A and 503B compounding pharmacy rules. The so-called “bulk drug substance” lists — particularly the Category 1 nominated substances — became central to ongoing regulatory debates that directly affect laboratory access to a range of commonly studied peptides.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. All peptides discussed are reference materials intended exclusively for in-vitro and preclinical laboratory research, not for human or animal use.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

GLP — 1 (S) 20MG

GLP-1 (S) 20MG — Research-Grade Reference Material GLP-1 (S) 20MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$125.00 ($93.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is the FDA’s Category 1 peptide classification?

Category 1 refers to nominated bulk drug substances that the FDA has determined are not appropriate for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. Placement on Category 1 does not eliminate a peptide from all research contexts — it specifically restricts pharmacy compounding for human use — but it has downstream effects on how certain peptides are sourced and studied in laboratory settings.

What does the FDA compounding ban on peptides mean for researchers?

The restrictions apply to licensed compounding pharmacies operating under 503A and 503B frameworks. For independent laboratory researchers procuring peptides as reference materials for in-vitro or preclinical study, the relevant regulatory framework is different. Research-use peptide suppliers operate under distinct channels that supply analytical reference compounds rather than compounded drug products intended for human administration.

Which peptides were placed on the FDA Category 1 list?

Several peptides were nominated for and placed under Category 1 restrictions between 2023 and 2025. These include BPC-157, TB-500 (thymosin beta-4 fragment), selank, semax, epithalon, and others. The exact list evolved through public comment periods and FDA deliberation, and researchers should consult the most current FDA bulk drug substances list for definitive status updates.

Can researchers still study Category 1 peptides?

Category 1 classification is specific to the compounding pharmacy context. Researchers operating within legitimate in-vitro and preclinical research frameworks — using peptides as analytical reference standards or laboratory reagents — are governed by different regulatory pathways. Research-use peptide suppliers provide compounds under these frameworks, distinct from compounded drug product channels.

What is the difference between a research peptide and a compounded drug?

A compounded drug is prepared by a licensed pharmacy for human administration. A research peptide is supplied as a laboratory reference material or analytical standard for use in preclinical, in-vitro, or investigational research contexts. These supply chains operate under different regulatory frameworks, and research peptide suppliers do not supply products for human consumption.

Are GLP-1 receptor agonist analogs regulated differently from other research peptides?

Peptides that bear structural or mechanistic similarity to existing approved drug compounds face heightened regulatory scrutiny in compounding contexts. For research suppliers, these compounds — available under coded research designations such as GLP-1 (S) and GLP-2 (T) — remain available as laboratory reference materials for preclinical mechanism studies. Their classification in compounding contexts is separate from their availability as research reagents.

How should researchers verify a peptide supplier’s compliance in 2026?

Researchers should prioritize suppliers who provide third-party certificates of analysis (COAs), publish purity testing data, clearly label products as research use only, and do not make human-use claims. Suppliers operating with transparent quality controls and documented sourcing are better aligned with responsible research procurement practices.

What peptides remain broadly available for research in 2026?

Many peptides studied across neuroscience, immunology, metabolic biology, and tissue remodeling research remain available through research-use channels. These include peptides such as GHK-Cu, NAD+, MOTS-C, CJC-1295, ipamorelin, PT-141, dihexa, selank, semax, oxytocin, and others — all supplied as laboratory reference materials with appropriate research-only labeling.

Understanding the Regulatory Framework: How FDA Classifies Peptides

The FDA’s approach to peptide regulation is multi-layered, operating across different statutory frameworks depending on the intended use of the compound. The most publicly discussed mechanism in 2024–2026 has been the 503A and 503B bulk drug substance nomination process, which governs what compounding pharmacies may legally prepare for patients.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

GLP — 1 (S) 20MG

$125.00 ($93.75 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Under this framework, nominated substances are sorted into categories. Substances placed on the Category 1 list are those the FDA has determined lack adequate evidence of safety or clinical appropriateness for compounded use, often because they are either inadequately studied in the compounding context or because a concern about safety data exists under that specific use pathway. This is a compounding-specific determination — not a blanket prohibition on the molecule’s existence or study in other research contexts.

Separate from compounding rules, the FDA regulates peptides that serve as new drug substances under the Investigational New Drug (IND) framework — a pathway that governs human trials for unapproved compounds. Laboratory researchers who are not conducting human trials, and who procure peptides as analytical reference materials, operate outside both the compounding and IND frameworks, under the broader context of research reagent procurement.

The 503A vs 503B Distinction

Section 503A governs traditional compounding pharmacies serving individual patient prescriptions. Section 503B governs outsourcing facilities that produce larger-scale compounded products. The 2024–2026 regulatory actions primarily targeted the 503A bulk substance list, and subsequent enforcement actions affected which peptides compounding pharmacies could continue to prepare. Researchers should understand that supplier channels for laboratory reference materials — not preparing products for patient use — are not the same as 503A/503B regulated entities.

Which Peptides Were Affected by Category 1 Restrictions?

Several peptides that had been widely used in compounding contexts entered regulatory scrutiny through the nomination and comment process. The following were among those placed under Category 1 consideration or finalized as restricted from 503A compounding:

BPC-157 — A synthetic pentadecapeptide derived from a gastric protein sequence, extensively studied in preclinical tissue and gastrointestinal research. BPC-157 research has examined a broad range of biological mechanisms, making it one of the most extensively investigated peptides in preclinical literature.
TB-500 (Thymosin Beta-4 Fragment) — A synthetic fragment studied in tissue remodeling and actin-regulation research. Detailed preclinical findings are documented in the TB-500 research guide.
Selank — A synthetic heptapeptide derived from tuftsin, studied in anxiolytic biology research. The Selank research guide outlines the mechanistic frameworks explored in preclinical models.
Semax — An ACTH-derived synthetic peptide explored extensively in neuropeptide biology, as detailed in the Semax definitive research guide.
Epithalon — A tetrapeptide studied in telomerase and aging biology research contexts.
Ipamorelin — A growth hormone secretagogue studied in GH pulse research, currently available as a laboratory reference material.
CJC-1295 — A GHRH analog studied in pulsatile GH release biology research models.

It is important to note that placement on the Category 1 compounding list does not eliminate these compounds from the research supply chain. They remain available from qualified research peptide suppliers as laboratory reference materials — the regulatory restriction applies specifically to pharmacy compounding for human administration.

BPC-157 – 10MG Nasal Spray for laboratory research →

TB-500 – 10MG Nasal Spray for laboratory research →

Peptides That Remain Broadly Available for Research in 2026

Despite the regulatory changes affecting the compounding sector, a large number of research peptides remain fully accessible through legitimate laboratory procurement channels. The following categories and examples remain in active research use:

Metabolic & Mitochondrial Biology Research

MOTS-C — A mitochondria-derived peptide studied in metabolic signaling research. As documented in MOTS-C preclinical research, studies have investigated its role in AMPK pathway modulation and mitochondrial communication.
GLP-1 (S) — A research-coded peptide analog explored in preclinical metabolic and pancreatic biology models.
GLP-2 (T) — A research-coded intestinotrophic peptide analog studied in gastrointestinal mucosal biology.
NAD+ — A coenzyme studied extensively in cellular energy metabolism and sirtuin biology research.

Skin, Connective Tissue & Remodeling Research

GHK-Cu — A copper-binding tripeptide with an extensive preclinical literature base covering collagen synthesis, wound biology, and antioxidant signaling. The GHK-Cu research guide covers its mechanistic biology in depth.
AHK-Cu — A related copper peptide investigated in hair follicle and scalp biology models.

Neuromodulatory & Cognitive Biology Research

Dihexa — A synthetic hexapeptide studied in HGF/c-Met pathway modulation and synaptic density research.
P21 — A CNTF-derived peptide fragment explored in neurogenesis and BDNF biology models.
Pinealon — A tripeptide studied in retinal and neuronal research contexts.

Growth Hormone Axis Research

CJC-1295 No DAC + Ipamorelin — A widely studied combination in pulsatile GH secretion research. The CJC-1295 + Ipamorelin stack research guide covers synergy findings in preclinical models.
CJC-1295 with DAC — Studied for its extended half-life kinetics in GH pulse research.

GLP-1 (S) – 10MG Nasal Spray for laboratory research →

MOTS-C – 10MG Nasal Spray for laboratory research →

GLP-2 (T) – 10MG Nasal Spray for laboratory research →

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

What This Means for Research Procurement in 2026

For laboratories and independent researchers, the 2025–2026 regulatory environment has underscored the importance of sourcing peptides from suppliers who clearly operate within the research reagent framework, not the compounding drug channel. Key indicators of a compliant research supplier include:

Explicit research-use-only labeling on all products and marketing materials
Third-party certificates of analysis (COAs) with purity data available per batch
Absence of human-use instructions, dosing guidance, or therapeutic claims
Transparent sourcing and manufacturing quality controls (HPLC purity verification, mass spectrometry confirmation)
No suggestion that products are intended to diagnose, treat, cure, or prevent any condition

The distinction between a compounding pharmacy and a research reagent supplier is not merely semantic — it is the foundation on which legitimate peptide research procurement rests. Researchers building compliant acquisition protocols in 2026 should document their procurement rationale, maintain records of research intent, and ensure institutional review processes are followed where applicable.

For researchers who require high-purity bacteriostatic water for reconstitution of lyophilized peptides, proper laboratory-grade reconstitution practices are essential. The bacteriostatic water research guide outlines quality standards relevant to laboratory peptide preparation.

Pfizer Hospira Bacteriostatic Water – 30mL for peptide reconstitution research →

The Research Supplier’s Role in the Post-2025 Landscape

Research peptide suppliers occupy a distinct position in the post-2025 regulatory environment. Unlike compounding pharmacies, they are not preparing drug products for patient administration — they are supplying analytical reference materials and laboratory reagents to researchers who study peptide biology in controlled, non-human research settings.

This distinction means that many peptides subject to 503A compounding restrictions remain available through research channels. However, responsible suppliers have also responded to the heightened regulatory scrutiny by reinforcing their compliance frameworks: strengthening COA documentation, removing any ambiguous human-use language, and ensuring that all product labeling, web content, and marketing unambiguously communicates the research-only nature of their inventory.

For the research community, this represents an opportunity to engage more rigorously with the regulatory framework — not to circumvent it, but to understand precisely where legitimate laboratory research fits within it. Peptide science remains an active and important area of preclinical investigation, and the availability of high-purity reference materials is essential to that scientific enterprise continuing to advance.

Where These Fit in Your Research Library

For researchers building a comprehensive peptide reference library, the following resources are directly relevant to the compounds and topics discussed in this guide:

GLP-1 (S) – 10MG Nasal Spray — For preclinical metabolic biology research
GLP-2 (T) – 10MG Nasal Spray — For gastrointestinal mucosal biology studies
MOTS-C – 10MG Nasal Spray — For mitochondrial signaling research

Browse the full catalog at SourcePeptides.co for the complete range of research-grade reference peptides available in 2026.

Final Takeaway: Navigating FDA Peptide Regulations in 2026

The FDA’s 2024–2026 regulatory actions on peptide compounding have introduced meaningful changes to one sector of the peptide market — licensed compounding pharmacies — while leaving the research reagent supply chain operating under a distinct and separate framework. For researchers, the critical takeaways are:

Category 1 classification applies to compounding pharmacy contexts, not to research reagent procurement.
Many affected peptides remain available as laboratory reference materials through compliant research suppliers.
Supplier compliance signals matter: COAs, research-only labeling, and absence of human-use claims are non-negotiable quality indicators.
Research documentation — recording procurement rationale, research intent, and institutional compliance — is increasingly important in the current environment.
The scientific value of peptide research endures: preclinical investigation across metabolic, neurological, tissue, and immune biology continues to advance regardless of compounding-sector regulatory shifts.

Researchers who engage proactively with this regulatory landscape — understanding what has changed, what has not, and where their procurement practices fit — are best positioned to continue meaningful peptide biology research throughout 2026 and beyond.

Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.